• Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s
• IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease
• The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO

In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://nnw.fm/Y1rLN). (https://cnw.fm/LGAZG). (https://ibn.fm/fg4A3). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s.

“We believe IGC-AD1 has the potential to revolutionize the treatment of the symptoms (agitation) of Alzheimer’s disease as the only natural low-dose THC-based formulation candidate currently undergoing FDA testing,” said IGC CEO Ram Mukunda. “Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe that the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as the APOE e4 a gene that increases the risk of developing Alzheimer’s.

“This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in a disease that has a global impact like Alzheimer’s,” Mukunda continued. “Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s disease.”

IGC’s Phase 2 trial, a multicenter, double-blind, randomized, placebo-controlled study of IGC-AD1, has started at two sites in the United States, with plans to add up to five additional sites throughout the U.S. and Canada; a site in South America is also being considered in order to increase population diversity and promote the inclusion of underrepresented populations.

According to the company, the trial will enroll 146 patients with one-half of participants, the “treated” group, receiving IGC-AD1, and the other half, the “control” group, receiving a placebo. “The goal of the trial is to evaluate and establish the efficacy of IGC-AD1 in helping patients with Alzheimer’s dementia reduce neuropsychiatric symptoms (‘NPS’) such as agitation, which effects 76% of individuals with Alzheimer’s,” the announcement stated. “Currently, there is no Food and Drug Administration (‘FDA’)-approved drug for treating agitation in dementia due to Alzheimer’s.”

According to the announcement, IGC-AD1 relies on low-doses of THC, a psychoactive cannabinoid, and another compound as active agents. In the pre-clinical trials, the formulation demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating a key protein that is responsible for Aβ plaques, a key hallmark of the disease.

India Globalization Capital develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://nnw.fm/IGC https://ibn.fm/IGC https://cnw.fm/IGC

• RNG is produced by decomposing and processing organic matter into compressed natural gas (“CNG”) to power vehicles, liquefied natural gas (“LNG”) for residential, commercial, and industrial uses
• RNG is completely compatible and fully interchangeable with conventional natural gas within existing pipeline networks
• EVGIF acquires, develops, builds, and owns a portfolio of RNG waste-to-energy and related infrastructure projects in British Columbia, Alberta, and Ontario

EverGen Infrastructure’s (TSX.V: EVGN) (OTCQX: EVGIF) renewable natural gas (“RNG”) infrastructure platform is tapping into the power of organic waste to power homes and vehicles across Canada. Starting in British Columbia on the west coast and Ontario towards the east, the company acquires, develops, builds, owns, and operates a portfolio of RNG waste-to-energy and related infrastructure projects with the aim of lowering greenhouse gases and powering a sustainable future. Converting organic waste into usable energy is not a new concept. The United States Clean Water Act of 1972 mandated the extraction of energy from methane – a colorless, odorless natural gas produced by certain human activities – before it was burned (https://ibn.fm/coCrr). As a result, hundreds of facilities across California currently produce electricity from a biogas-fueled engine. EVGIF is dedicated to making similar technological advances in Canada. RNG is a high-quality, completely compatible gas alternative that is fully interchangeable with conventional natural gas within the existing pipeline network. It is produced by decomposing and processing organic matter into compressed natural gas (“CNG”) to power vehicles or liquefied natural gas (“LNG”) that can be used for residential, commercial, and industrial purposes. EverGen aims to bring RNG technology to Canadian homes and businesses by building an infrastructure network of over 20 facilities within five years. The company’s current footprint comprises five RNG and/or organic processing facilities that include Net Zero Waste Abbottsford, Fraser Valley Biogas, and Sea to Sky Soils in British Columbia. Towards the east, the company has a 67% ownership in Alberta-based GrowTEC and a 50% stake in Ontario-based Project Radius. RNG produced at Net Zero Waste Abbottsford, Fraser Valley Biogas, and GrowTEC is bought via long-term offtake agreements by FortisBC – the largest natural gas distributor in British Columbia. With a focus on the East, EVGIF recently acquired a 50 percent interest in Project Radius – a portfolio of RNG development projects in Ontario that can collectively produce approximately 1.7 million RNG GJ/year. “When you add it all together, we’ve got a business capable of delivering $30 million of EBITDA from the portfolio that we have in front of us, and we see 25+ projects in Canada that could deliver 4x growth beyond that”, said EVGIF CEO Chase Edgelow in a recent interview on The Bell2Bell Podcast (https://ibn.fm/jmDCF). “There’s a tremendous amount of opportunity in this space right now.” Based in Vancouver, British Columbia, EverGen is an established independent RNG producer committed to developing Canada’s RNG infrastructure. With projects across the country, the company is emerging as a leader committed to powering a sustainable, net-zero future based on sustainable energy sources. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities
• BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness
• BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where he discussed recent successful results from the preclinical in vivo study, additional pipeline plans for other NanoAb therapeutics, and the company’s derisked R&D strategy

Mainland China is experiencing a fresh wave of COVID-19 infections sweeping some of its most populous provinces. The SARS-CoV-2 virus, which causes COVID-19, has been spreading fast since the Chinese government in early December lifted restrictions that were aimed at containing infections (https://ibn.fm/SzDKu).

Results of the policy have been dire. Early this year, officials reported the Omicron variant had already infected 89% of the Henan province’s 100 million residents. This comes after late December reports that the industrial province of Zhejiang was battling around 1 million new daily COVID-19 infections, a number that was expected to double in the days ahead (https://ibn.fm/oPJGX). “High levels of SARS-CoV-2 infections and increased pressure on healthcare services in China are expected in the coming weeks due to low population immunity and the relaxation of non-pharmaceutical intervention,” stated a January 3 article by the European Center for Disease Prevention and Control (“ECDC”) (https://ibn.fm/O1JfL).

For Amir Reichman, the CEO of biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV), the ongoing outbreak in China and frequent emerging variants have reinforced an undeniable fact: “that continuous development of innovative and safe therapeutics for COVID-19 is the most effective and economical way to control this disease.” Coupled with the fact that there uptake of COVID-19 vaccinations and boosters is waning, there is a significant unmet need that BiondVax intends to solve with its inhaled nanosized antibody (“NanoAb”) COVID-19 therapy.

Developed as part of a strategic research collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, the alpaca-derived NanoAb therapies are designed to address diseases with large underserved medical needs and attractive commercial opportunities, including COVID-19, asthma, psoriasis, psoriatic arthritis, and other large market disorders. As part of the development process, BiondVax is conducting a preclinical in vivo proof-of-concept study of its inhaled NanoAb COVID-19 therapy, with the results expected to inform the design of the first-in-human clinical trial of the inhaled COVID-19 therapeutic planned for Q4 2023.

In a recent news release announcing the latest results from the preclinical study, BiondVax reported that the presence of the SARS-CoV-2 virus in the lungs of hamsters treated with the inhaled NanoAb was below detectable levels and significantly (p<0.0005) less than the amount of virus detected in the control group. The study showed that six days after infection, hamsters treated with the inhaled NanoAb had over 30x lower SARS-CoV-2 viral titers in their lungs than the placebo group as measured by median tissue culture infectious dose (TCID50). This highly significant data suggests that BiondVax’s NanoAbs may have the breakthrough potential to dramatically reduce the risk of transmission. According to the announcement, these results were corroborated by PCR testing (https://ibn.fm/KLXl4).

“These lung viral titer results indicate that our inhaled NanoAbs essentially eliminated viral presence in the lungs and led to a shorter and milder illness,” commented Dr. Tamar Ben-Yedidia, BiondVax’s Chief Science Officer (“CSO”). “This data is unequivocal and exciting. We’re looking forward to continuing this study this month by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive) treatment.”

The most recent announcement builds on results from the same study reported November 29, 2022. These earlier results showed that the control group’s weight post-infection declined by 12.01% on average compared to the pre-infection weight. In contrast, the weight of hamsters that received the inhaled NanoAb therapeutic declined by only 3.80% on average, a highly statistically significant result (p<0.001) (https://ibn.fm/93ykQ). Weight loss in hamsters is a commonly accepted indicator of COVID illness severity, and was also used as a proxy in earlier studies for Regeneron’s (NASDAQ: REGN) REGEN‑COV COVID antibody cocktail treatment and Pfizer’s (NYSE: PFE) blockbuster COVID treatment Paxlovid.

According to BiondVax, the preclinical study is set to continue in January 2023 and will test lower therapeutic doses and a prophylactic dose of the NanoAb, in addition to evaluating safety parameters. Moreover, the company will this year also conduct a preclinical toxicity study to evaluate safety. BiondVax also intends to scale up its manufacturing processes to produce the NanoAbs in their in-house GMP facility in preparation for the planned Q4 2023 first-in-human Phase 1/2a clinical trial.

Meanwhile, Mr. Reichman recently presented at the Biotech Showcase Conference held between January 9-11, 2023. The presentation focused on the recent successful preclinical in vivo trial results, additional pipeline plans for the other NanoAb therapeutics, and BiondVax’s derisked R&D strategy (https://ibn.fm/HDady).

BiondVax is focused on developing, manufacturing, and commercializing innovative large market immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Eloro Resources’ CEO, Thomas Larsen recently attended the Mines and Money London conference as a featured speaker during the event.
• As part of the forum, Larsen participated in a one-on-one interview with Commodity-TV, during which he elaborated on the prospects of the company’s Bolivian silver – tin polymetallic project, Iska Iska
• With initial exploratory drilling analysis taking place on the site since September of 2020, Larsen expressed his optimism on the resource metal concentration within the Iska Iska project
• Eloro will look to publish its inaugural resource estimation by March 2023 prepared by Micon International

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company focused solely on its key Bolivian property, ISKA ISKA, was a featured presenter at the recent Mines and Money London conference. Held between Nov. 29 – Dec. 1, 2022, the Mines and Money London forum has emerged as Europe’s largest and most in-depth mining conference dedicated towards touting the global sustainability agenda. With a focus on energy transition, ESG, decarbonisation and the circular economy, the production of tin, zinc and silver – crucial ingredients needed to fuel the ongoing green energy transition, has gained particular relevance in years. As part of the conference agenda, this year’s event played host to an in-depth interview carried out by Commodity-TV featuring Eloro Resources CEO, Thomas Larsen (https://ibn.fm/RDMFs). Iska Iska is located in the prolific Potosi region of Southern Bolivia, an area renowned for its world-class silver and tin deposits. ISKA ISKA is located a mere 180 kilometers south of the Cerro Rico deposit, which is widely acknowledged as one the world’s most prolific silver deposits having produced over 2.5 billion silver ounces since the sixteenth century and still producing today. Having optioned the deposit from the tract’s owners in January 2020, Eloro agreed to pay a gross consideration amounting to $10 million to the title holder by 2024 to acquire a 100% interest in the project. With just under half of the figure already disbursed, Eloro will seek to make the balance payment of $5.6 million at or before June 2024. Eloro commenced the inaugural drill program at the Iska Iska site in Sept. 2020 and since then, has drilled over 120 holes and 85,000 meters within the property. These initial discoveries in late 2020 convinced the company of the site’s relative potential. Between Nov. 2020 and Jan. 2021, the company found that its initial holes – most of which were between 250 and 300 meters in length, were delivering bulk tonnage of 150 silver grams equivalent per ton – a level of silver concentration which has been found to be economically viable in the past. Larsen further revealed that Eloro Resources was acquiring the Mina Casiterita and Mina Hoyada properties, that adjoin the existing Iska Iska deposit towards the property’s western and south-western boundaries. These two properties have the same mineral characteristics as that of ISKA ISKA, allowing a potential extension of the overall deposit, but just as importantly, easier access to the potential tin deposit below.  Larsen explained that artisanal mining in the 1960’s had revealed the Mina Casiterita property to contain significant amounts of tin.  As such, it came as little surprise when Larsen stated during the interview that geophysical data now suggested that the high-grade feeder zone could be extended for another 500 metres to 2,000 metres, which the final drill holes had initially tested in the 2022 program.” Following the purchase and post the near-term conclusion of exploratory drilling within the Iska Iska deposit, the company has now set their sights on the continuation of exploring this sizable deposit and the completion of the inaugural resource b by March 2023, a development which could mark the next step in Eloro Resources’ commercial journey. For more information, visit the company’s website at www.EloroResources.com. NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Singular Research has released an updated report on Hillcrest Energy Technologies detailing the many accomplishments of the company during the 2H 2022
• Hillcrest completed its first working prototype of its ZVS inverter, which has attracted the attention of majors in the electric mobility, including Hercules Electric Mobility and a Tier 1 automotive supplier
• Singular estimates the innovation may lead to revenue for Hillcrest later this year, rising to $10.6 million in 2024, a figure used to calculate a valuation of 20 cents per share, up 177% from the current price

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean-technology company developing transformative power conversion technologies and control system solutions for next-generation EVs and electrical systems, was the subject of an updated report by Singular Research released on January 4, 2023. In a report in August, Singular speculated on the prospects of Hillcrest’s “potential breakthrough” inverter technology and how it could attract the attention of majors in the automotive industry (https://ibn.fm/qPMJT). The January report detailed the partnerships that have already come to fruition as Hillcrest continues to hit critical milestones, underscoring Singular reiterating its Buy–Venture rating and a $0.20 price target from current level of $0.0722. Singular covered the extremely productive second half of the year for Hillcrest, which was highlighted by several substantial accomplishments, including completion of the first commercial prototype of their 250-kilowatt, 800-volt Zero Voltage Switching (“ZVS”) inverter. The prototype and tech undergirded the signing of a Memorandum of Understanding with Hercules Electric Mobility, a major step towards commercialization. Per the MOU, the companies are collaborating to build and test an electric powertrain system featuring a Hillcrest 250kW, 800V inverter that has been optimized for a Hercules powertrain. Early in 2022, Coach Marine Group chose the Hercules 200kW e-drive system as the electric propulsion system for its Coach and Xcursion branded electric pontoon boats. Coach plans to manufacture up to 1,500 electric pontoon boats annually using the Hercules system, which could have a meaningful impact on Hillcrest. Singular sees the potential for this relationship to lead to monetization of Hillcrest technology later this year. To the point of revenue, Singular posits Hillcrest to realize at least $200 per unit (a conservative estimate of ~2-4% of the total cost of a high-end inverter), which Singular models to approximately $750,000 in revenue for the fourth quarter of 2023. Looking further ahead, Singular projects revenue to increase quarter-over-quarter to result in about $10.6 million in revenue for 2024. Singular forecasts Hillcrest to be EBITDA positive in the second quarter of 2024. Hercules wasn’t the only catalyst covered for commercialization efforts. In October, Hillcrest disclosed a partnership with an anonymous global Tier 1 automotive supplier for the purpose of integrating an optimized version of Hillcrest’s 250kW, 800V ZVS inverter technology into a new powertrain system for the auto markets. Throughout the year, the partners will test different configurations with the goal of commercializing a nominal 350kW product utilizing the benefits of Hillcrest’s technology. To fund its continued development, Hillcrest recently closed a temporary warrant exercise program and first tranche of a non-brokered private placement, raising $1.87 million. Other topics covered in the report included the addition of James Bolen as Chief Commercialization Officer, adding 30+ years’ executive-level experience to the team, and a revenue multiple analysis valuation. Using a discounted rate, Singular values Hillcrest at 20 cents per share, implying a 177% upside from the price per share at the time of the report. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

Professionals and executives from the pharma, medical device, biotech, and life science medical fields, are invited to attend the premiere Clinical Research in Latin America Summit by DGE, streaming online on February 9-10th, 2023. Latin America is a crucial growth zone for the future of clinical research and has numerous ethnic groups, meaning greater representation of diverse groups in clinical trials. The challenges lie in areas like logistics, resources, and publications. Get all your questions answered and gain valuable guidance from a diverse community of experts at the Clinical Research in Latin America Summit by DGE.The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. DGE events is devoted to offering a viable forum for discussion and interaction with the medical industry. Timely and important topics are discussed by experts on DGE’s platforms, with an immersive audience, and live-streamed on. The events are attended by specialists of global acclaim with profound experience and knowledge in their respective fields.

At the Clinical Research In Latin America Summit, industry leaders and experts will offer their valuable advice on successfully employing strategies to conduct clinical research and execute viable clinical trials throughout the region. In the evolving landscape, it is critical to consider demographics covering diverse areas like Latin America in clinical trials—keeping these population-concentrated areas in mind, it is important to design futuristic strategies in clinical trials. Industry-leading experts will discuss ways to overcome hurdles to achieve greater patient retention and enrollment in Latin America.

Important issues to be discussed at the event:

• Clarifying the status of the current landscape and that of the highly skilled HCPs
• Understanding how to explore the different multiple regulatory frameworks
• Better engagement across different sectors of regional cross-collaborations
• Embracing robust medical strategies to reduce the gaps in patient knowledge
• Ways to perform the task of eradicating hurdles of local research capacity
• Learning novel ideas to make up for the low volume of publications

Join leading experts in the biopharma sector as they unveil actionable strategies for study coordination, site interaction, patient enrollment, partnership design, regulatory compliance, and much more. This DGE event aims to build a robust research pipeline through improved collaboration strategies, renewed public outreach, and a commitment to diversity.

To learn more, please visit https://ibn.fm/xYEq8

Connect with TA pros and HR leaders at the Talent Acquisition Week being held this January in Southern California, as industry leaders deliver keynote speakers and hold discussions on the future of recruiting. For the last 10 years, the Social Recruiting Strategies Conference (#SRSC) has focused on providing TA pros and HR managers the trending HR practices, global recruiting marketing trends, candidate engagement, plus related tools and technologies through practitioner-to-practitioner sessions, panel discussions and case studies. This year, SRSC returns as a flagship event of the Talent Acquisition Week being held in January 31 to February 2, 2023. The larger-than-life event will showcase 3 talent attraction events live and in person — SRSC, Talent Sourcing Strategies Summit, and Employer Branding Strategies Conference. These power-packed shows will bring together eminent industry leaders and HR stalwarts on a common platform, offering networking and talent acquisition. In addition, registered TA Week attendees are eligible to enter a talent attraction video for the event’s showcase contest. They will also have access to view video submissions and vote on the videos of their choice. The winner will be announced on stage at TA Week and receive a full-year Amplify VMS license with unlimited users and unlimited video creation. Why attend Talent Acquisition Week?

• TA pros can avail this tremendous opportunity to access the best industry practices for employer branding, identifying and recruiting, all under one roof
• Get valuable insights from peers and influencers on candidate messaging and engagement
• Tips on sourcing, employer branding, social recruiting as well as in-person networking with TA personnel
• Understand ways to improve candidates’ recruiting and retention experiences
• Learn effective information from fellow talent attraction pros that you can apply to your strategy now
• Hire and retain the best talent to derive the maximum from your TA strategy

The agenda of the #TAW is extensive with conferences and workshops on achieving recruiting and retention success. Attendees will learn the best hiring techniques and effective global talent strategies. Workshops will also be conducted on building employer brands. Other conference topics include discussion on winning the TA trifecta and improving recruiting experiences. Keynote panel discussions include ways o attract and hire top talent. The Expo floor offers a robust forum where attendees can explore more interesting topics and avenues. To learn more, please visit https://ibn.fm/iBAai

Professionals and executives from the biopharma, health organizations, CROs, Digital Solutions, Policy Developers, and Medical Device Companies, are invited to attend the Health Equity In Clinical Trials Congress being held in Boston, February 22-23, 2023. Participants will get access to a wide spectrum of healthcare opportunities and the chance to meet and connect with veterans of the industry. In the two main event days, 25+ leading industry speakers will gather on this forum to share their valuable insights in 5 keynote sessions, and will discuss tactful approaches to drive meaningful change for underrepresented communities through meaningful cross-industry networks and scaling equity initiatives. Attendees will get deeper insights from these equity change-makers to more fully understand strategies for expanding diversity, equity and inclusion programs, through industry action and technology. The opening panel discussion topic will be on biopharma advancements for inclusive investigations and health equity programs, conducted by leading clinical trial experts in the industry. Why attend the Clinical Trials Congress?

• Meet peers, advocates and industry experts and grow your business network
• Learn and understand from case studies, success stories, and experiences shared by your peers and leaders
• Make a list of all pointers that form a foundation for your business; strategies, roadmaps, and other insights offered by the stalwarts at the congress
• Attending the congress is a business investment that will also contribute to the personal growth of professionals and executives by increasing their knowledge base

Those interested in pitching their business or services at the conference can get curated packages that range from presenting their expertise on the main stage to hosting a private dinner. Interested candidates can partner with the event organizers at Kisaco Research to showcase their brand and make valuable new connections. There are 3 main categories: Thought Leadership, Branding & Networking. If you would like to register a team of 3 or more, please email events@kisacoresearch.com for a discount coupon code before registering. To learn more, please visit https://ibn.fm/8tTzM

• Google will change its requirements for product ads on January 20, 2023, to allow the promotion of FDA-approved pharmaceuticals containing CBD and topical hemp-derived CBD products in California, Colorado, and Puerto Rico
• Non-FDA-approved CBD topicals will require certification from LegitScript, which will test THC compliance and review the third-party Certificate of Analysis of each product to be promoted
• With the growing acceptance of cannabis, REZYFi is positioned in the financial industry as one of the first cannabis mortgage bankers in the United States

In the United States, cannabis-related products are growing in acceptance, even in mainstream media. A recent announcement from Google advises that the company will update its Dangerous Products and Services and Healthcare and Medicines Google Ads policies on January 20, 2023. Google will allow for the promotion of FDA-approved pharmaceuticals containing cannabidiol (“CBD”) and topical, hemp-derived CBD products with a tetrahydrocannabinol (“THC”) content of 0.3% or less in California, Colorado, and Puerto Rico. Non-FDA-approved topicals will require verification through LegitScript. Google will continue to disallow ads promoting other CBD-based products, including supplements, food additives, and inhalants (https://ibn.fm/M9LvO). For non-FDA-approved CBD topicals, LegitScript’s certification will require that products sought to be advertised: (1) provide samples for compliance testing of legal THC limits, and (2) provide a third-party Certificate of Analysis. LegitScript charges a fee for processing and monitoring applicants. However, through March 31, 2023, the company is offering a waiver of application fees with promo code “CBDPRODapp” for product certification (https://ibn.fm/OFs69). Since 2016, when California legalized cannabis, the state has shown a growing acceptance – which has been working its way across the country. According to Pew Research Center, nearly 90% of adults in the US favor cannabis, with 59% showing favor for recreational and medical use and 30% showing favor for medicinal use only (https://ibn.fm/bUevz). Not all industries have embraced the acceptance of cannabis, though, with many traditional financial institutions still reticent to serve the state-licensed cannabis industry. Disrupting the financial industry and favoring cannabis-related companies is REZYFi, a growth mortgage origination and specialized financing company in the United States. REZYFi originates, structures, and invests in first mortgage loans and alternative structured financings secured by commercial real estate properties. The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing. REZYFi works through two wholly-owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent, and servicing operation. Through these subsidiaries, REZYFi plans to use its corporate strengths – experience, a network of independent brokers, and proprietary technology – to provide an essential source of growth within the cannabis industry, positioning itself as one of the first cannabis mortgage bankers in the United States. Combined, the medical and recreational use of cannabis are expected to reach a market value of $33 billion by the end of 2022, with retail cannabis sales projected to reach $52.6 billion by 2026 (https://ibn.fm/rLtya). The growth is attributed to more state voters accepting cannabis for recreational and medicinal use. The growing acceptance of cannabis for medicinal and recreational use is driving markets in various industries, creating a call for services, including financing options – which REZYFi is uniquely positioned to answer. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals
• Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts
• To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes
• The company has since expanded the device’s capabilities in keeping with developments in remote patient monitoring technology and insurance company recognition to monitor falls, wandering, and other health concerns

Following a year of wearable technology advances together with a rebranding and restructuring drive, medical patient location device developer MetAlert (OTC: MLRT) is working with shareholders to demonstrate the “significant potential” for market value found in MetAlert’s GPS two-way tracking technologies.

MetAlert developed its patented flagship GPS SmartSole shoe insoles a decade ago as a solution for those at risk of wandering or becoming lost or disoriented due to Alzheimer’s disease, dementia, autism, or traumatic brain injury.

The SmartSole later also found utility as a safeguard for people at risk of kidnapping, such as government employees, journalists and corporate executives. But during the early months of the COVID pandemic, the company noted an additional opportunity as a remote health solution to help patients avoid having to visit crowded doctor clinics when possible, thereby avoiding health risks from other patients that might be more dangerous than the condition being treated.

The result, the expanded capabilities of the SmartSole plus(R), provides a means of establishing a Bluetooth connection with a wearable “hub” for collecting health data in real-time wherever users may be and communicating that information to medical providers.

“Converging factors, such as wide adoption of telehealth and related third-party payer approval, the ability for wireless networks to transmit large amounts of data in nanoseconds, and advancements in artificial intelligence, led us to make the decision to expand our tracking and monitoring platform,” CEO and Founder Patrick Bertagna stated in a Jan. 5 letter to the shareholders (https://ibn.fm/jxUCt). “MetAlert provides a complete indoor/outdoor remote patient monitoring biometric health and wellness solution, with potential for insurance reimbursement and possibly, a long-term predictive A.I. big data play.”

During 2022, the company also changed its name and ticker symbol, plus conducted a reverse split, and prepared for further developments in 2023, including rolling out the hub to the public along with a small GPS tracker shorter than a credit card that will provide the same functionality as the insoles with a longer (two weeks) battery life between charging.

During the past year, MetAlert also eliminated its variable convertible debt and signed a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing the company’s new 3D Infrared indoor remote patient monitoring system called RoomMate, which provides fall detection to caregivers.

MetAlert also engaged Joseph Gunnar & Co., LLC as its financial adviser to help the company prepare for uplisting to a national stock exchange and exploring acquisitions that may accelerate MetAlert’s growth.

“We are now taking dramatic steps to align the public-facing (stock) part of the company with the operations and vision of the company,” Bertagna wrote. “Strategic acquisitions, expanding our products and services, and increasing our revenues per user (“RPU”), should help set us on a path toward continued success in the coming months and years. Moreover, aligning with new technologies could open possibilities for crucial data analysis that has the potential to revolutionize how we conduct and manage healthcare worldwide.”

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT